

1626


IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-544US

In Re Application Of:

PALLE et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/596,059	5/26/2006	Unknown	26,815	Unknown	1271

Title: **PHOSPHODIESTERASE INHIBITORS**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);


OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-544US

In Re Application of: **PALLE et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/596,059	5/26/2006	Unknown	26,815	Unknown	1271

Title: **PHOSPHODIESTERASE INHIBITORS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

5/4/2007

Signature of Person Mailing Correspondence

Christine Kenedy-Renner

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: 5/4/2007

George E. Heibel, Esq.
Reg. No. 42,648

CUSTOMER NO. 26815

CC:

INFORMATION DISCLOSURE CITATION


Docket No.: RLL-544US | Serial No.: 10/596,059

Applicants: PALLE et al.

Filed: 5/26/2006

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,686,434	11/11/1997	Kleinman	514	92	
	A2	5,869,511	2/9/1999	Cohan et al.	514	378	
	A3	6,114,367	9/5/2000	Cohan et al.	514	378	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	DE 199 09 785	9/7/2000	Germany	C07D	413/04	
	B2	WO 95/14680	6/1/1995	PCT	C07D	261/04	
	B3	WO 95/14681	6/1/1995	PCT	C07D	261/04	
	B4	WO 95/24398	9/14/1995	PCT	C07D	261/04	
	B5	WO 02/081447	10/17/2002	PCT	C07D	209/46	
	B6	WO 02/100332	12/19/2002	PCT	A61K		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Sutherland and Rall, "The Relation of Adenosine-3',5'-Phosphate and Phosphorylase to the Actions of Catecholamines and Other Hormones", <i>Pharmacological Reviews</i> , <u>12</u> :265-299 (1960)
C2	Beavo and Reifsnyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <i>Trends in Pharmacological Sciences</i> , <u>11</u> :150-155 (1990)
C3	Nicholson et al., "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , <u>12</u> :19-27 (1991)
C4	Vergheese et al, "Anti-Neutrophil Activity of Cyclic Nucleotide Phosphodiesterase Inhibitors with Varying Cardiotonic Potencies", <i>Journal of Molecular Cell Cardiology</i> , <u>12</u> (suppl. II):S61 (1989)
C5	T.J. Trophy, "Directions for new Anti-Asthma Drugs", 37, eds. S.R. O'Donnell and G.A. Persson, Birkhäuserverlag (1988)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION



Docket No.: RLL-544US Serial No.: 10/596,059

Applicants: PALLE et al.

Filed: 5/26/2006

Group:

C6	Ashton et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues", <i>Journal of Medicinal Chemistry</i> , <u>37</u> (11):1696-1703 (1994)
C7	DiSanto and Heaslip, "Identification and Stabilization of Large Molecular Weight PDE-IVs from U937 Cells", <i>Biochemical and Biophysical Research Communications</i> , <u>197</u> (3):1126-1131 (1993)
C8	Greene and Wuts, <i>Protective Groups in Organic Synthesis</i> . 2nd ed. New York:John Wiley and Sons.
C9	Molina and de Aguiar, "Synthesis of new 4,5-dihydroisoxazoles with potential anti-inflammatory activity," <i>Heterocyclic Communications</i> , <u>9</u> (5):535-538 (2003)
C10	Rai and Hassner, "Intermolecular 1,3-dipolar cycloaddition of nitrile oxides with vinyl acetate and acrylonitrile," <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> , <u>36B</u> (3):242-245 (1997) - Abstract Only
C11	Fihi et al, "Reaction des methylene γ -butyrolactones avec les arylnitriloxydes. Evolution inattendue du bisadduit issu de la 5-methylene(5H)furan-2-one", <i>Bulletin des Societes Chimiques Belges</i> , <u>104</u> (1):55-62 (1995) - No translation
C12	Rai et al., "A Convenient Method of the Generation of Nitrile Oxide and its Application to the Synthesis of 2-Isoxazolines", <i>Organic Preparations and Procedures International</i> , <u>24</u> (1):91-94 (1992)
C13	Al-Timari and Fišera, "Regioselective synthesis of C-nucleosides by 1,3-dipolar cycloaddition of arylnitrile oxides to 5,6-dideoxy-1,2-O-isopropylidene- α -D-xylo-hex-5-enofuranose", <i>Carbohydrate Research</i> , <u>218</u> :121-127 (1991)
C14	Clerici et al., "Isothiazole Dioxides: Synthesis and Inhibition of <i>Trypanosoma brucei</i> Protein Farnesyltransferase", <i>Bioorganic & Medicinal Chemistry Letters</i> , <u>12</u> (16):2217-2220 (2002)
C15	Hafez et al., "New pyrazolines, isoxazolines and sulfides from 4,7-dimethoxy-5-acetyl-6-hydroxybenzofuran (Khellinone) and their antimicrobial activities", <i>Pakistan Journal of Scientific and Industrial Research</i> , <u>33</u> (5-6):197-200 (1990) - Abstract Only
C16	Khalil et al., "Synthesis and microbial activity of 5-heterocyclo-8-hydroxyquinolines", <i>Journal of the Indian Chemical Society</i> , <u>67</u> (10):821-823 (1990) - Abstract Only
C17	Koroleva et al., "Cycloreversion of 5-(4-pyridyl)-2-isoxazolines in reactions with bases", <i>Russian Journal of Organic Chemistry</i> , <u>33</u> (1):108-112 (1997) (Translation of Zhurnal Organicheskoi Khimii - Abstract Only)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	